Dr. Reddy's Laboratories enters into license agreement with Pharmazz

22 Mar 2024 Evaluate

Dr. Reddy's Laboratories has entered into a license agreement with Pharmazz, Inc. (Pharmazz), a U.S. based biopharmaceutical company developing and commercialising drug products to treat critically ill patients, to commercialise the first-in-class innovative drug Centhaquine in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by the Drugs Controller General of India (DCGI).

As per the agreement, Dr. Reddy's has received exclusive rights to market and distribute Centhaquine in India. Pharmazz will be entitled to upfront payments and royalties. Dr. Reddy’s will market the product under the brand name Lyfaquin, which it shall own. In addition to India, Dr. Reddy’s also receives marketing rights for Lyfaquin from Pharmazz for Nepal. 

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

5872.35 1.35 (0.02%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.